Analysis of adrenal masses by 18F-FDG positron emission tomography scanning

International Journal of Clinical Practice

Volumn 61, Issue 5, 2007, Pages 802-809

  Han, S J ^a   Kim, T S ^a   Jeon, S W ^a   Jeong, S J ^a   Yun, M ^a   Rhee, Y ^a   Kang, E S ^a   Cha, B S ^a   Lee, E J ^a   Lee, H C ^a   Lim, S K ^a  

^a Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADRENAL CANCER; ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; ADULT; ARTICLE; CANCER LOCALIZATION; CANCER SIZE; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; PHEOCHROMOCYTOMA; PREDICTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; TUMOR VOLUME;

ADRENAL GLAND NEOPLASMS; ADULT; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34247177446     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01220.x     Document Type: Article

References (32)

1. Barzon L, Boscaro M. Diagnosis and management of adrenal incidentalomas. J Urol 2000; 163: 398-407.
2. Kloos RT, Gross MD, Francis IR et al. Incidentally discovered adrenal masses. Endocr Rev 1995; 16: 460-84.
3. Herrera MF, Herrera MF, Grant CS et al. Incidentally discovered adrenal tumors: an institutional perspective. Surgery 1991; 110: 1014-21.
4. Hussain S, Belldegrun A, Seltzer SE et al. Differentiation of malignant from benign adrenal masses: predictive indices on computed tomography. Am J Roentgenol 1985; 144: 61-5.
5. Baker ME, Spritzer C, Blinder R et al. Benign adrenal lesions mimicking malignancy on MR imaging: report of two cases. Radiology 1987; 163: 669-71.
6. Paivansalo M, Lahde S, Merikanto J, Kallionen M. Computed tomography in primary and secondary adrenal tumors. Acta Radiol 1988; 29: 519-22.
7. Gross MD, Shapiro B, Bouffard JA et al. Distinguishing benign from malignant euadrenal masses. Ann Intern Med 1988; 109: 613-8.
8. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004; 25: 568-80.
9. Yun M, Kim W, Alnafisi N et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001; 42: 1795-9.
10. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied cases. Cancer 1950; 3: 74-85.
11. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. Am J Roentgenol 2002; 179: 559-68.
12. Korobkin M, Giordano TJ, Brodeur FJ et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996; 200: 743-7.
13. Krestin GP, Friedmann G, Fischbach R et al. Evaluation of adrenal masses in oncologic patients: dynamic contrast-enhanced MR vs CT. J Comput Assist Tomogr 1991; 15: 104-10.
14. Dunnick NR, Korobkin M, Francis I. Adrenal radiology: distinguishing benign from malignant adrenal masses. Am J Roentgenol 1996; 167: 861-7.
15. Korobkin M, Brodeur FJ, Francis IR et al. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. Am J Roentgenol 1998; 170: 747-52.
16. Reinig JW, Doppman JL, Dwyer AJ et al. Adrenal masses differentiated by MR. Radiology 1986; 158: 81-4.
17. Outwater EK, Siegelman ES, Radecki PD et al. Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. Am J Roentgenol 1995; 165: 579-83.
18. Rubello D, Bui C, Casara D et al. Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002; 147: 13-28.
19. 18F]fluoro-2-deoxy-d-glucose. J Comput Assist Tomogr 1993; 17: 582-9.
20. Boland GW, Goldberg MA, Lee MJ et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 194: 131-4.
21. Erasmus JJ, Patz EF Jr, McAdams HP et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 1997; 168: 1357-60.
22. Maurea S, Klain M, Mainolfi C et al. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 2001; 42: 884-92.
23. Mansmann G, Lau J, Balk E et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25: 309-40.
24. Rao SK, Caride VJ, Ponn R et al. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med 2004; 29: 300-2.
25. Becherer A, Vierhapper H, Potzi C et al. FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 2001; 16: 289-95.
26. Shulkin BL, Thompson NW, Shapiro B et al. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212: 35-41.
27. Neumann DR, Basile KE, Bravo EL et al. Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb. J Comput Assist Tomogr 1996; 20: 312-6.
28. Kushner BH, Yeung HW, Larson SM et al. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-405.
29. Shulkin BL, Hutchinson RJ, Castle VP et al. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199: 743-50.
30. 18F-FDG. J Nucl Med 2004; 45: 972-9.
31. 11C hydroxyephedrine PET. Radiology 2004; 230: 423-8.
32. 18F] Fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38: 6-8.